Background illustration for clinical trials search

Merck Clinical Trials

Find clinical trials for Merck. Search for Merck clinical trials in different cities and states across the United States.

Filter
Active & Responsive

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for
Breast Neoplasms
Location: Rimouski, Boston MA, Quebec, Stony Brook NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06312176

Phase 3, Recruiting
Active & Responsive

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

for
Crohn's Disease
Location: Kentville, Boston MA, Providence RI, Levis,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 16 - 70+

Code: NCT06430801

Phase 3, Recruiting
Active & Responsive

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

for
Triple Negative Breast Neoplasms
Location: Quebec, Chicoutimi, Mineola NY, New York NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06841354

Phase 3, Recruiting
Active & Responsive

A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).

for
Healthy
Location: Columbus OH, Springfield MO, Kansas City MO, Omaha NE,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 12 - 30

Code: NCT06655324

Phase 1, Recruiting
Active & Responsive

A Study of V132 in Healthy Older Participants (V132-001)

for
Healthy
Location: East Greenwich RI, Hallandale FL, Hollywood FL,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 50 - 70+

Code: NCT07712575

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Study of V118E in Healthy Participants (V118E-003)

for
Healthy
Location: Hallandale FL, Springfield MO
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18 - 49

Code: NCT07168915

Phase 1, Recruiting
Active & Responsive

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

for
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Location: Hillsborough NJ, Montreal, Philadelphia PA,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07266831

Phase 2, Phase 3, Recruiting
Active & Responsive

A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)

for
Insomnia
Location: Providence RI, New Haven CT, Marlton NJ,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18 - 70

Code: NCT06655883

Phase 3, Recruiting
Active & Responsive

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

for
Coronavirus Disease (COVID-19)
Location: The Bronx NY, New York NY, Teaneck NJ, Newark NJ,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06667700

Phase 3, Recruiting
Active & ResponsiveNew

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)

for
Diabetic Retinopathy, Macular Edema
Location: Hagerstown MD, Charleston SC, Winston-Salem NC,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07705607

Phase 3, Recruiting
Active & ResponsiveNew

A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)

for
Severe Renal Impairment, Healthy
Location: Miami Lakes FL
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18 - 70+

Code: NCT07734610

Phase 1, Recruiting
Active & Responsive

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

for
Generalized Myasthenia Gravis
Location: Farmington CT, Burlington VT, Washington D.C. DC,
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Sex: All

Age: 18+

Code: NCT06463587

Phase 3, Recruiting
Active & Responsive

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

for
Non-Muscle Invasive Bladder Cancer
Location: Sherbrooke, Baltimore MD, Toronto, Tampa FL, Chicago IL,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06637423

Phase 1, Phase 2, Recruiting
Active & Responsive

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

for
Breast Neoplasms, Breast Cancer
Location: Norfolk VA, Nashville TN, Skokie IL, Houston TX,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06797635

Phase 2, Recruiting
Active & Responsive

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

for
Esophageal Squamous Cell Carcinoma
Location: East Syracuse NY, Pittsburgh PA, Tucson AZ,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05319730

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

for
Carcinoma, Non-Small-Cell Lung
Location: Halifax, Boston MA, Norwich CT, New Haven CT, Quebec,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06623422

Phase 3, Recruiting
Active & Responsive

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

for
Non-small Cell Lung Cancer
Location: Albany NY, Fairfax VA, Raleigh NC, Lisle IL, Lincoln NE
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07554339

Phase 3, Recruiting
Active & Responsive

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

for
Non-small Cell Lung Cancer
Location: New Haven CT, White Plains NY, Albany NY, Montreal,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07513376

Phase 3, Recruiting
Active & Responsive

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

for
Urothelial Carcinoma
Location: New York NY, Toronto, Pittsburgh PA, Cleveland OH,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05562830

Phase 1, Phase 2, Recruiting
Active & Responsive

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

for
Bladder Cancer
Location: New York NY, Cleveland OH, Chicago IL,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07232602

Phase 1, Phase 2, Recruiting